ReviewFrontiers in medicine2025
Revolutionizing renal biopsy: the emerging role of omics and artificial intelligence in nephrology.
Review in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Artificial intelligence in small tissue biopsies: diagnostic applications, histochemical integration, and methodological challenges in surgical pathology.Histochemistry and cell biology · 2026Review
- [Histology and more-modern nephropathology].Innere Medizin (Heidelberg, Germany) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal biopsies remain indispensable in the diagnosis and management of renal diseases, offering critical histopathological insights that guide clinical decisions. Recent advances in artificial intelligence (AI) and multi-omics technologies have begun to transform renal pathology by enabling deeper molecular profiling, enhanced diagnostic precision, and personalized treatment strategies. Despite these promising developments, challenges such as implementation complexity, cost, and limited integration into routine clinical workflows have slowed widespread adoption. Notably, a significant gap exists in the literature regarding how these modern technologies are applied to maximize the diagnostic and prognostic value of renal biopsies. This mini-review highlights emerging applications of AI and omics in renal biopsy interpretation, emphasizing their potential to transform diagnostic approaches in precision nephrology. It aims to inform nephrologists, renal pathologists, and researchers about the evolving landscape of renal diagnostics, while highlighting areas for further clinical integration and interdisciplinary collaboration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.